Sequoia Financial Advisors LLC Has $1.52 Million Stock Holdings in Becton, Dickinson and Company $BDX

Sequoia Financial Advisors LLC decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 25.1% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 10,070 shares of the medical instruments supplier’s stock after selling 3,374 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Becton, Dickinson and Company were worth $1,524,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of BDX. Larson Financial Group LLC lifted its position in Becton, Dickinson and Company by 1.7% during the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after acquiring an additional 53 shares during the last quarter. Brown Lisle Cummings Inc. grew its position in shares of Becton, Dickinson and Company by 9.2% in the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after purchasing an additional 54 shares during the last quarter. Elevation Point Wealth Partners LLC increased its stake in shares of Becton, Dickinson and Company by 3.7% during the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after purchasing an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC lifted its holdings in Becton, Dickinson and Company by 1.1% during the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock worth $834,000 after purchasing an additional 62 shares during the last quarter. Finally, NorthRock Partners LLC lifted its holdings in Becton, Dickinson and Company by 2.0% during the 2nd quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier’s stock worth $499,000 after purchasing an additional 65 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on BDX. TD Cowen upped their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $187.67.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $185.78 on Wednesday. The business has a fifty day moving average price of $173.65 and a two-hundred day moving average price of $160.52. The stock has a market capitalization of $51.19 billion, a PE ratio of 55.96, a P/E/G ratio of 12.89 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Insider Activity

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Garrison sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 8,005 shares of company stock worth $1,423,580. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD’s products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.